Targeted drug trial aims to slow advanced cancers by blocking a faulty gene signal
NCT ID NCT06390826
Summary
This study is testing a drug called sunitinib in patients with advanced cancers that have a specific change (mutation) in a gene called cKIT. The drug aims to block the faulty signal from this mutated gene that tells cancer cells to grow, which could help slow or stop the cancer's spread. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.